COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

SCHEDULE OF RENT EXPENSE STRAIGHT-LINE BASIS

Rent expense is recorded on the straight-line basis and in cost of manufacturing in the unaudited condensed consolidated statements of operations. Rent expense is as follows:

Lease	2025		2024		2025		2024
	For the Three Months Ended December 31,				For the Nine Months Ended December 31,
Lease	2025		2024		2025		2024
Ludlow-144	$	158,317	$	152,602	$	474,951	$	455,632
Pompano-2311		—		2,696		—		18,870
NBV-610		4,562		7,303		13,688		7,303
Rent expense		4,562		7,303		13,688		7,303

SCHEDULE OF FUTURE MINIMUM RENTAL PAYMENTS

The table below shows the future minimum rental payments, exclusive of taxes, insurance and other costs:

Years ending March 31,	Operating Lease Amount			Financing Lease Amount			Total
Remainder of 2026	$	165,581		$	128,039		$	293,620
2027		667,307			484,151			1,151,458
2028		666,207			479,337			1,145,544
2029		440,159			438,045			878,204
2030		—			13,740			13,740
Less: interest		(262,354	)		(215,710	)		(478,064	)
Present value of lease payments	$	1,676,900		$	1,327,602		$	3,004,502

SCHEDULE OF WEIGHTED -AVERAGE REMAINING TERM AND THE WEIGHTED-AVERAGE DISCOUNT RATE

The weighted-average remaining lease term and the weighted-average discount rate of our leases were as follows:

	For the Nine Months Ended December 31,
Lease Term and Discount Rate	2025			2024
Remaining lease term (years)
Operating leases		2.9			3.9
Finance leases		3.1			4.1
Discount rate
Operating leases		10.0	%		10.0	%
Finance leases		9.5	%		9.5	%

ELITE PHARMACEUTICALS INC /NV/ 10-Q